CLOs on the Move

Celldex

www.celldex.com

 
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body`s immune response. Celldex Therapeutics (NASDAQ: CLDX) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. The Company`s pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have ...
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.celldex.com
  • 53 Frontage Road Suite 220
    Hampton, NJ USA 08827
  • Phone: 908.454.7120

Executives

Name Title Contact Details
Freddy Jimenez
 Senior Vice President and General Counsel Profile

Similar Companies

PrecisionMed

PrecisionMed Inc. is a Solana Beach, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Biothera

Biothera is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Southern Biotech Associates

Southern Biotech Associates is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Sherlock Biosciences

Sherlock Biosciences aims to disrupt molecular diagnostics with better, faster, affordable tests. With our unique Engineering Biology platforms, we are on the cusp of solving challenges ranging from faster pathogen detection and simpler testing for cancer to improved food safety. We envision a world where our products will enable users to make more effective decisions in any environment, whether in hospitals, industrial settings, the developing world, or at home. Our team and founders include Engineering Biology pioneers with world-leading expertise in CRISPR and Synthetic Biology, diagnostic industry veterans, and disease-area authorities. Together, they provide an unparalleled set of capabilities that are transforming molecular diagnostics in clinical and non-clinical settings.

Nuvalent

Nuvalent is creating precisely targeted therapies for patients with cancer designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with exquisite target selectivity to overcome resistance, minimize adverse events, and drive more durable responses. Nuvalent is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive NSCLC, along with multiple discovery-stage research programs.